Aqualung Therapeutics Corp.
TUCSON, AZ · Founded 2021 · CIK 0001933303 · Biotech · Private
Novel therapeutic drugs for diseases with unmet medical need
aqualungtherapeutics.com →- Grants
- $18M
- 25 awards
- Sector median: 1
- Raised
- $3.1M
- 1 Form D · Jun 2022
- 52 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 1 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | $750,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | $1,500,000 | |
| Federal grant | Department of Health and Human Services · Phase II · eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | $300,001 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP) | $265,096 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP) | $265,096 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | $750,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | $2,000,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | $1,000,000 | |
| Private capital raised | Form D · SEC | $3,100,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | $259,613 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | $269,233 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting the P Selectin Pathway to Improve ARDS Survival | $259,613 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting the P Selectin Pathway to Improve ARDS Survival | $259,613 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | $975,215 | |
| Federal grant | Department of Health and Human Services · Phase II · A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | $1,500,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | $1,500,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | $809,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | $809,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | $975,215 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | $808,999 | |
| Federal grant | Department of Health and Human Services · Phase II · A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | $957,594 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progression | $284,699 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3371 | SERVA ENERGY, INC. | — | $7.1M |
| 3372 | SwanBio Therapeutics | — | — |
| 3373 | Akston Biosciences Corp | — | $17M |
| 3374 | Aqualung Therapeutics Corp. | — | $3.1M |
| 3375 | Concerto Biosciences, Inc. | — | $16M |
| 3376 | UNCO THERAPEUTICS LLC | — | — |
| 3377 | Inspira Therapeutics, Inc | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Joe GarciaDirector · Executive Officer
- Stan MieleDirector · Executive Officer
Patents
- Anti-human Nicotinamide Phosphoribosyltransferase (nampt) Antibodiesapplication
- Anti-human Nicotinamide Phosphoribosyltransferase (nampt) Antibodiesgranted
- Anti-nampt Antibodies And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.